anti gdf15 Search Results


human gdf-15 antibody  (Bio-Techne corporation)
94
Bio-Techne corporation human gdf-15 antibody
Human Gdf 15 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/Human+GDF-15+Antibody/bio-techne+corporation___af957
Average 94 stars, based on 1 article reviews
human gdf-15 antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
cytokine growth differentiation factor 15  (Atlas Antibodies)
92
Atlas Antibodies cytokine growth differentiation factor 15
Cytokine Growth Differentiation Factor 15, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/Anti-GDF15/pm32614434-68-57-67
Average 92 stars, based on 1 article reviews
cytokine growth differentiation factor 15 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier
gdf15  (Bio-Rad)
91
Bio-Rad gdf15
Gdf15, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/Rabbit+anti+GDF15/pm36740767-33-14-18
Average 91 stars, based on 1 article reviews
gdf15 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier
serum gdf 15  (Boster Bio)
93
Boster Bio serum gdf 15
Serum Gdf 15, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/Human+GDF-15+Recombinant+Protein/10__2399_slash_raed__15__s02010216-4362-0-2
Average 93 stars, based on 1 article reviews
serum gdf 15 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
nrg 1  (Boster Bio)
93
Boster Bio nrg 1
Nrg 1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/Anti-GDF15+Antibody/pmc04525875-94-2-3
Average 93 stars, based on 1 article reviews
nrg 1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
rabbit anti-mouse/rat gdf-15  (Forschungszentrum gmbh)
90
Forschungszentrum gmbh rabbit anti-mouse/rat gdf-15
Rabbit Anti Mouse/Rat Gdf 15, supplied by Forschungszentrum gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/rabbit+anti+mouse+rat+gdf+15/pmc03540664-23-0-14
Average 90 stars, based on 1 article reviews
rabbit anti-mouse/rat gdf-15 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
anti-gdf15 monoclonal antibody ponsegromab  (CSNpharm Inc)
90
CSNpharm Inc anti-gdf15 monoclonal antibody ponsegromab
Anti Gdf15 Monoclonal Antibody Ponsegromab, supplied by CSNpharm Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/anti+gdf15+monoclonal+antibody+ponsegromab/pm39985040-103-1-9
Average 90 stars, based on 1 article reviews
anti-gdf15 monoclonal antibody ponsegromab - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
antibody anti-gdf15  (US Biological Life Sciences)
90
US Biological Life Sciences antibody anti-gdf15
Antibody Anti Gdf15, supplied by US Biological Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/antibody+anti+gdf15/pmc06754141-59-10-11
Average 90 stars, based on 1 article reviews
antibody anti-gdf15 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
anti-gdf15 antibody  (Sanyou Biopharmaceuticals Co Ltd)
90
Sanyou Biopharmaceuticals Co Ltd anti-gdf15 antibody
(A - E) SD male rat serum <t>GDF15</t> concentrations measured from experiments: Cisplatin/TCMCB07 ( A ), 5-Fluorouracil /TCMCB07 ( B ), Cyclophosphamide/TCMCB07 ( C ), Vincristine/TCMCB07 ( D ), and Doxorubicin/TCMCB07 ( E ). ( F ) Schematic of experimental design. All SD male rats were treated with cisplatin chemotherapy via IP injection at a dose of 5.0 mg/kg (1 st cycle) or 3.0 mg/kg (2 nd and 3 rd cycles) once per week for three cycles. All the rats received SC injections twice (2x) daily with either saline or TCMCB07 (3 mg/kg/day) from day 0 to 21. Additionally, all the rats received SC injections twice (2x) weekly with either IgG or GDF15 antibody from day 0 to 21. The dose of TCMCB07 was 3 mg/kg/day, and the dose of GDF15 antibody was 10 mg/kg. Initial and terminal body composition was measured using MRI before and after treatments. Food intake and body weight were monitored daily throughout entire experimental period (day 0-21). At the end of the experiment, tissues were harvested following euthanasia. ( G ) Daily food intake, ( H ) Cumulative food intake, ( I ) Weekly food intake, ( J ) Total food intake after treatment of cisplatin and TCMCB07 in combination with GDF15 antibody. All data in ( A - E ), ( I ), and ( J ) are expressed with each dot representing one sample, and all data in ( G ) and ( H ) are expressed as mean ± SEM for each group. ( A ) and ( B ), n = 11-12. ( C - E ), n = 5-6, as blood samples were collected from half of the animals in these experiments. ( G - J ), n = 10-11. ( G ) and ( H ), *: Cisplatin/saline+IgG vs Cisplatin/saline+GDF15 antibody, #: Cisplatin/saline+IgG vs Cisplatin/TCMCB07+GDF15 antibody, &: Cisplatin/saline+GDF15 antibody vs Cisplatin/TCMCB07+GDF15 antibody. *, #, &, P < 0.05; **, ##, &&, P < 0.01; ***, ###, &&&, P < 0.001; ****, ####, &&&&, P < 0.0001. One-way ANOVA ( A - E ), ( I ), and ( J ). Two-way ANOVA
Anti Gdf15 Antibody, supplied by Sanyou Biopharmaceuticals Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/monoclonal+anti+gdf15+antibody+mab1/bio_rxiv__2024__09__14__613069-210-0-5
Average 90 stars, based on 1 article reviews
anti-gdf15 antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
anti-gdf-15 antibodies  (SAW Instruments GmbH)
90
SAW Instruments GmbH anti-gdf-15 antibodies
(A - E) SD male rat serum <t>GDF15</t> concentrations measured from experiments: Cisplatin/TCMCB07 ( A ), 5-Fluorouracil /TCMCB07 ( B ), Cyclophosphamide/TCMCB07 ( C ), Vincristine/TCMCB07 ( D ), and Doxorubicin/TCMCB07 ( E ). ( F ) Schematic of experimental design. All SD male rats were treated with cisplatin chemotherapy via IP injection at a dose of 5.0 mg/kg (1 st cycle) or 3.0 mg/kg (2 nd and 3 rd cycles) once per week for three cycles. All the rats received SC injections twice (2x) daily with either saline or TCMCB07 (3 mg/kg/day) from day 0 to 21. Additionally, all the rats received SC injections twice (2x) weekly with either IgG or GDF15 antibody from day 0 to 21. The dose of TCMCB07 was 3 mg/kg/day, and the dose of GDF15 antibody was 10 mg/kg. Initial and terminal body composition was measured using MRI before and after treatments. Food intake and body weight were monitored daily throughout entire experimental period (day 0-21). At the end of the experiment, tissues were harvested following euthanasia. ( G ) Daily food intake, ( H ) Cumulative food intake, ( I ) Weekly food intake, ( J ) Total food intake after treatment of cisplatin and TCMCB07 in combination with GDF15 antibody. All data in ( A - E ), ( I ), and ( J ) are expressed with each dot representing one sample, and all data in ( G ) and ( H ) are expressed as mean ± SEM for each group. ( A ) and ( B ), n = 11-12. ( C - E ), n = 5-6, as blood samples were collected from half of the animals in these experiments. ( G - J ), n = 10-11. ( G ) and ( H ), *: Cisplatin/saline+IgG vs Cisplatin/saline+GDF15 antibody, #: Cisplatin/saline+IgG vs Cisplatin/TCMCB07+GDF15 antibody, &: Cisplatin/saline+GDF15 antibody vs Cisplatin/TCMCB07+GDF15 antibody. *, #, &, P < 0.05; **, ##, &&, P < 0.01; ***, ###, &&&, P < 0.001; ****, ####, &&&&, P < 0.0001. One-way ANOVA ( A - E ), ( I ), and ( J ). Two-way ANOVA
Anti Gdf 15 Antibodies, supplied by SAW Instruments GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/anti+gdf+15+antibodies/us11634482-610-5-18
Average 90 stars, based on 1 article reviews
anti-gdf-15 antibodies - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
monoclonal anti-human gdf15  (BioAgilytix)
90
BioAgilytix monoclonal anti-human gdf15
(A - E) SD male rat serum <t>GDF15</t> concentrations measured from experiments: Cisplatin/TCMCB07 ( A ), 5-Fluorouracil /TCMCB07 ( B ), Cyclophosphamide/TCMCB07 ( C ), Vincristine/TCMCB07 ( D ), and Doxorubicin/TCMCB07 ( E ). ( F ) Schematic of experimental design. All SD male rats were treated with cisplatin chemotherapy via IP injection at a dose of 5.0 mg/kg (1 st cycle) or 3.0 mg/kg (2 nd and 3 rd cycles) once per week for three cycles. All the rats received SC injections twice (2x) daily with either saline or TCMCB07 (3 mg/kg/day) from day 0 to 21. Additionally, all the rats received SC injections twice (2x) weekly with either IgG or GDF15 antibody from day 0 to 21. The dose of TCMCB07 was 3 mg/kg/day, and the dose of GDF15 antibody was 10 mg/kg. Initial and terminal body composition was measured using MRI before and after treatments. Food intake and body weight were monitored daily throughout entire experimental period (day 0-21). At the end of the experiment, tissues were harvested following euthanasia. ( G ) Daily food intake, ( H ) Cumulative food intake, ( I ) Weekly food intake, ( J ) Total food intake after treatment of cisplatin and TCMCB07 in combination with GDF15 antibody. All data in ( A - E ), ( I ), and ( J ) are expressed with each dot representing one sample, and all data in ( G ) and ( H ) are expressed as mean ± SEM for each group. ( A ) and ( B ), n = 11-12. ( C - E ), n = 5-6, as blood samples were collected from half of the animals in these experiments. ( G - J ), n = 10-11. ( G ) and ( H ), *: Cisplatin/saline+IgG vs Cisplatin/saline+GDF15 antibody, #: Cisplatin/saline+IgG vs Cisplatin/TCMCB07+GDF15 antibody, &: Cisplatin/saline+GDF15 antibody vs Cisplatin/TCMCB07+GDF15 antibody. *, #, &, P < 0.05; **, ##, &&, P < 0.01; ***, ###, &&&, P < 0.001; ****, ####, &&&&, P < 0.0001. One-way ANOVA ( A - E ), ( I ), and ( J ). Two-way ANOVA
Monoclonal Anti Human Gdf15, supplied by BioAgilytix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/sulfo+tag+conjugated+polyclonal+anti+human+gdf15/pm39148430-106-12-29
Average 90 stars, based on 1 article reviews
monoclonal anti-human gdf15 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
human gdf-15 duoset elisa  (Bio-Techne corporation)
96
Bio-Techne corporation human gdf-15 duoset elisa
(A - E) SD male rat serum <t>GDF15</t> concentrations measured from experiments: Cisplatin/TCMCB07 ( A ), 5-Fluorouracil /TCMCB07 ( B ), Cyclophosphamide/TCMCB07 ( C ), Vincristine/TCMCB07 ( D ), and Doxorubicin/TCMCB07 ( E ). ( F ) Schematic of experimental design. All SD male rats were treated with cisplatin chemotherapy via IP injection at a dose of 5.0 mg/kg (1 st cycle) or 3.0 mg/kg (2 nd and 3 rd cycles) once per week for three cycles. All the rats received SC injections twice (2x) daily with either saline or TCMCB07 (3 mg/kg/day) from day 0 to 21. Additionally, all the rats received SC injections twice (2x) weekly with either IgG or GDF15 antibody from day 0 to 21. The dose of TCMCB07 was 3 mg/kg/day, and the dose of GDF15 antibody was 10 mg/kg. Initial and terminal body composition was measured using MRI before and after treatments. Food intake and body weight were monitored daily throughout entire experimental period (day 0-21). At the end of the experiment, tissues were harvested following euthanasia. ( G ) Daily food intake, ( H ) Cumulative food intake, ( I ) Weekly food intake, ( J ) Total food intake after treatment of cisplatin and TCMCB07 in combination with GDF15 antibody. All data in ( A - E ), ( I ), and ( J ) are expressed with each dot representing one sample, and all data in ( G ) and ( H ) are expressed as mean ± SEM for each group. ( A ) and ( B ), n = 11-12. ( C - E ), n = 5-6, as blood samples were collected from half of the animals in these experiments. ( G - J ), n = 10-11. ( G ) and ( H ), *: Cisplatin/saline+IgG vs Cisplatin/saline+GDF15 antibody, #: Cisplatin/saline+IgG vs Cisplatin/TCMCB07+GDF15 antibody, &: Cisplatin/saline+GDF15 antibody vs Cisplatin/TCMCB07+GDF15 antibody. *, #, &, P < 0.05; **, ##, &&, P < 0.01; ***, ###, &&&, P < 0.001; ****, ####, &&&&, P < 0.0001. One-way ANOVA ( A - E ), ( I ), and ( J ). Two-way ANOVA
Human Gdf 15 Duoset Elisa, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gdf15/Human+GDF-15+DuoSet+ELISA/custom%40dy957%4037909034
Average 96 stars, based on 1 article reviews
human gdf-15 duoset elisa - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


(A - E) SD male rat serum GDF15 concentrations measured from experiments: Cisplatin/TCMCB07 ( A ), 5-Fluorouracil /TCMCB07 ( B ), Cyclophosphamide/TCMCB07 ( C ), Vincristine/TCMCB07 ( D ), and Doxorubicin/TCMCB07 ( E ). ( F ) Schematic of experimental design. All SD male rats were treated with cisplatin chemotherapy via IP injection at a dose of 5.0 mg/kg (1 st cycle) or 3.0 mg/kg (2 nd and 3 rd cycles) once per week for three cycles. All the rats received SC injections twice (2x) daily with either saline or TCMCB07 (3 mg/kg/day) from day 0 to 21. Additionally, all the rats received SC injections twice (2x) weekly with either IgG or GDF15 antibody from day 0 to 21. The dose of TCMCB07 was 3 mg/kg/day, and the dose of GDF15 antibody was 10 mg/kg. Initial and terminal body composition was measured using MRI before and after treatments. Food intake and body weight were monitored daily throughout entire experimental period (day 0-21). At the end of the experiment, tissues were harvested following euthanasia. ( G ) Daily food intake, ( H ) Cumulative food intake, ( I ) Weekly food intake, ( J ) Total food intake after treatment of cisplatin and TCMCB07 in combination with GDF15 antibody. All data in ( A - E ), ( I ), and ( J ) are expressed with each dot representing one sample, and all data in ( G ) and ( H ) are expressed as mean ± SEM for each group. ( A ) and ( B ), n = 11-12. ( C - E ), n = 5-6, as blood samples were collected from half of the animals in these experiments. ( G - J ), n = 10-11. ( G ) and ( H ), *: Cisplatin/saline+IgG vs Cisplatin/saline+GDF15 antibody, #: Cisplatin/saline+IgG vs Cisplatin/TCMCB07+GDF15 antibody, &: Cisplatin/saline+GDF15 antibody vs Cisplatin/TCMCB07+GDF15 antibody. *, #, &, P < 0.05; **, ##, &&, P < 0.01; ***, ###, &&&, P < 0.001; ****, ####, &&&&, P < 0.0001. One-way ANOVA ( A - E ), ( I ), and ( J ). Two-way ANOVA

Journal: bioRxiv

Article Title: Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss

doi: 10.1101/2024.09.14.613069

Figure Lengend Snippet: (A - E) SD male rat serum GDF15 concentrations measured from experiments: Cisplatin/TCMCB07 ( A ), 5-Fluorouracil /TCMCB07 ( B ), Cyclophosphamide/TCMCB07 ( C ), Vincristine/TCMCB07 ( D ), and Doxorubicin/TCMCB07 ( E ). ( F ) Schematic of experimental design. All SD male rats were treated with cisplatin chemotherapy via IP injection at a dose of 5.0 mg/kg (1 st cycle) or 3.0 mg/kg (2 nd and 3 rd cycles) once per week for three cycles. All the rats received SC injections twice (2x) daily with either saline or TCMCB07 (3 mg/kg/day) from day 0 to 21. Additionally, all the rats received SC injections twice (2x) weekly with either IgG or GDF15 antibody from day 0 to 21. The dose of TCMCB07 was 3 mg/kg/day, and the dose of GDF15 antibody was 10 mg/kg. Initial and terminal body composition was measured using MRI before and after treatments. Food intake and body weight were monitored daily throughout entire experimental period (day 0-21). At the end of the experiment, tissues were harvested following euthanasia. ( G ) Daily food intake, ( H ) Cumulative food intake, ( I ) Weekly food intake, ( J ) Total food intake after treatment of cisplatin and TCMCB07 in combination with GDF15 antibody. All data in ( A - E ), ( I ), and ( J ) are expressed with each dot representing one sample, and all data in ( G ) and ( H ) are expressed as mean ± SEM for each group. ( A ) and ( B ), n = 11-12. ( C - E ), n = 5-6, as blood samples were collected from half of the animals in these experiments. ( G - J ), n = 10-11. ( G ) and ( H ), *: Cisplatin/saline+IgG vs Cisplatin/saline+GDF15 antibody, #: Cisplatin/saline+IgG vs Cisplatin/TCMCB07+GDF15 antibody, &: Cisplatin/saline+GDF15 antibody vs Cisplatin/TCMCB07+GDF15 antibody. *, #, &, P < 0.05; **, ##, &&, P < 0.01; ***, ###, &&&, P < 0.001; ****, ####, &&&&, P < 0.0001. One-way ANOVA ( A - E ), ( I ), and ( J ). Two-way ANOVA

Article Snippet: Anti-GDF15 antibody was manufactured by Sanyou Bio (Shanghai, China), based on the published protein sequence of the mAB1 GDF15 antibody, GDF15 antibody (GDF15-001, Ponsegromab, Pfizer).

Techniques: Injection, Saline

( A ) Daily body weight gain (% initial), ( B ) Weekly body weight gain (% initial), ( C ) Fat mass gain (% initial), ( D ) Lean mass gain (% initial), ( E ) Heart mass (% initial body weight), ( F ) Gastrocnemius mass (% initial body weight) after treatment of cisplatin+saline+IgG, cisplatin+saline+GDF15 antibody (Ab), or cisplatin+TCMCB07+GDF15 Ab. All data in ( A ) are expressed as mean ± SEM for each group, and all data in ( B - F ) are expressed with each dot representing one sample. n = 10-11. ( A ), *: Cisplatin/saline+IgG vs Cisplatin/saline+GDF15 antibody, #: Cisplatin/saline+IgG vs Cisplatin/TCMCB07+GDF15 antibody, &: Cisplatin/saline+GDF15 antibody vs Cisplatin/TCMCB07+GDF15 antibody. * P < 0.05; **, ##, &&, P < 0.01; ***, P < 0.001; ****, ####, P < 0.0001. Two-way ANOVA ( A ), One-way ANOVA ( B - F ).

Journal: bioRxiv

Article Title: Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss

doi: 10.1101/2024.09.14.613069

Figure Lengend Snippet: ( A ) Daily body weight gain (% initial), ( B ) Weekly body weight gain (% initial), ( C ) Fat mass gain (% initial), ( D ) Lean mass gain (% initial), ( E ) Heart mass (% initial body weight), ( F ) Gastrocnemius mass (% initial body weight) after treatment of cisplatin+saline+IgG, cisplatin+saline+GDF15 antibody (Ab), or cisplatin+TCMCB07+GDF15 Ab. All data in ( A ) are expressed as mean ± SEM for each group, and all data in ( B - F ) are expressed with each dot representing one sample. n = 10-11. ( A ), *: Cisplatin/saline+IgG vs Cisplatin/saline+GDF15 antibody, #: Cisplatin/saline+IgG vs Cisplatin/TCMCB07+GDF15 antibody, &: Cisplatin/saline+GDF15 antibody vs Cisplatin/TCMCB07+GDF15 antibody. * P < 0.05; **, ##, &&, P < 0.01; ***, P < 0.001; ****, ####, P < 0.0001. Two-way ANOVA ( A ), One-way ANOVA ( B - F ).

Article Snippet: Anti-GDF15 antibody was manufactured by Sanyou Bio (Shanghai, China), based on the published protein sequence of the mAB1 GDF15 antibody, GDF15 antibody (GDF15-001, Ponsegromab, Pfizer).

Techniques: Saline